Alendronate
Osteoporosis treatment equally lowers hip fracture risk for both men and women
Osteoporosis treatment reduces the risk for hip fractures for older men just as well as it does for older women, according to a study published in Journal of Bone and Mineral Research.
Risedronate discontinuation may increase mortality risk after hip fracture
Older adults who sustain a hip fracture after discontinuing risedronate following at least 5 years of treatment adherence have a higher post-fracture mortality risk than those who continue using risedronate, according to study data.
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Top in endocrinology: Novel weight loss drug; denosumab vs. alendronate for osteoporosis
Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of receiving BI 456906, a novel glucagon/GLP-1 receptor agonist, during a phase 2 clinical trial, according to a press release.
Denosumab bests alendronate as first-line therapy for fracture prevention in osteoporosis
Postmenopausal women with osteoporosis who use denosumab as a first-line therapy have lowers risk for fractures compared with women who use alendronate, according to an industry press release.
Romosozumab improves BMD, reduces fracture risk in women with osteoporosis and CKD
Romosozumab improved bone mineral density at the lumbar spine, total hip and femoral neck, and reduced the relative risk for fractures in women with osteoporosis and mild-to-moderate chronic kidney disease, according to study data.
Alendronate therapy associated with depression, anxiety
Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for depression and anxiety, according to an analysis of adverse events reports.
‘Consistent reductions’ in moderate, severe vertebral fractures with romosozumab therapy
Romosozumab is associated with marked reductions in all vertebral fracture grades, and these are sustained after transition to antiresorptive agents, post hoc analyses from the FRAME and ARCH studies show.
Alendronate may reduce risk for type 2 diabetes
Alendronate, a drug commonly used to treat osteoporosis, may help protect against type 2 diabetes, according to a presenter at the European Association for the Study of Diabetes virtual meeting.